Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders

Journal of Dermatological Treatment

Volumn 22, Issue 2, 2011, Pages 90-101

  Hession, Meghan T ^a   Gottlieb, Alice B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

healing; infection; psoriasis; psoriatic arthritis; surgical complications; tumor necrosis factor antagonists

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; METHOTREXATE; PLACEBO; SCLEROPROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANASTOMOSIS LEAKAGE; ANKYLOSING SPONDYLITIS; CROHN DISEASE; DISEASE SEVERITY; ENTERITIS; EVIDENCE BASED MEDICINE; HOST RESISTANCE; HUMAN; INFECTION RISK; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; NONHUMAN; PATHOPHYSIOLOGY; PELVIS ABSCESS; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SURGICAL INFECTION; TREATMENT OUTCOME; ULCERATIVE COLITIS; WOUND HEALING; WOUND INFECTION;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DERMATOLOGIC AGENTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952369824     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546630903585090     Document Type: Review

References (70)

1. About psoriasis National Psoriasis Foundation [accessed 2009 Sep 15]. Available from: learn01.
2. Ellerin T, Rubin RH, Weinblatt ME. Infection and anti-tumor necrosis factor a therapy. Arthritis Rheum. 2003;48(11): 3013-3022. (Pubitemid 37409310)
3. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Wilmore D, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst. 1988;80(13):1039-1044.
4. Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy. 2005;25(11): 1566-1591. (Pubitemid 41566917)
5. Mooney DP, O'Reilly M, Gamelli RL. Tumor necrosis factor and wound healing. Ann Surg. 1990;211:124-129. (Pubitemid 20063197)
6. Lee, R, Efron DT, Udaya T, Stuelten C, Moldawer LL, Abouhamze A, et al. Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. Wound Repair Regen. 2000;8:547-553. (Pubitemid 32141458)
7. Rapala KT, Vaha-Kreula MO, Heino JJ, Vuorio EI, Laato MK. Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts. Experientia. 1996;52(1):70-74.
8. Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, San A, et al. The local effects of cachectin.tumor necrosis factor on wound healing. Ann Surg. 1991;214(2):175-180.
9. Cowin AJ, Hatzirodos N, Rigden J, Fitridge R, Belford DA. Etanercept decreases tumor necrosis factor-alpha activity in chronic wound fluid. Wound Repair Regen. 2006;14: 421-426. (Pubitemid 44266598)
10. Barrientos S, Stojadinovic O, Golinko MS, Brem H, Tomic- Canic M. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16:585-601.
11. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2008;58(5):826-850.
12. Enbrel (etanercept) for subcutaneous injection [monograph on internet]. Thousand Oaks, CA: Immunex Corp.; c. 2006 [accessed 2009 Sep 10]. Available from: .
13. Humira (adalimumab) [monograph on internet]. North Chicago, IL: Abbott Laboratories; 2007 Jul [accessed 2009 Sep 10]. Available from: .
14. Infliximab package insert [monograph on internet] [accessed 2009 Sep 10]. Available from: .
15. Simponi (golimumab): product insert (US) [monograph on internet]. Centocor Ortho Biotech, Inc. [accessed 2009 Sep 10]. Available from: .
16. European Medicine Agency (EMEA). Summary of product characteristics: Enbrel [accessed 10 Sep 2009]. Available from: .
17. Gottlieb AB, Leonardi CL, Goffe BS, Ortonne JP, van der Kerkhof PC, Zitnik R, et al. Etanercept monotherapy in patients with psoriasis: A summary of safety, based on an integrated multistudy database. J Am Acad Dermatol. 2006;54(3 suppl 2):S92-S100. (Pubitemid 43243480)
18. Patel T, Gordon KB. Adalimumab: Efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004;17: 427-431. (Pubitemid 39390596)
19. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate-tosevere psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106-115. (Pubitemid 350298146)
20. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007;56(1):31.e1-e15.
21. Gordon K, Tyring S, Gu Y, Okum M. Psoriasis patients treated continuously with adalimumab: Efficacy and safetyresults from months 12 to 18 [abstract]. J Am Acad Dermatol. 2008;58(2):AB129.
22. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003;48:319-324. (Pubitemid 36277998)
23. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005;41(suppl):S194- S198. (Pubitemid 41022090)
24. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098-1104.
25. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565-2570. (Pubitemid 36118917)
26. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade. Mayo Clin Proc. 2008;83:181-194. (Pubitemid 351303102)
27. Fleischman R, Iqbai I, Nandeshwar P, Quniceno A. Safety and efficacy of modifying anti-rheumatic agents: Focus on the benefits and risk of etanercept. Drug Safety. 2002;25: 173-197. (Pubitemid 34492938)
28. Gisondi PG. Biologic therapies in psoriasis: A new therapeutic approach. Autoimmun Rev. 2007;6(8):515-519.
29. Darabi K, Jaiswal R, Hostetler S, Bechtel M, Zirwas M. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. J Drugs Dermatol. 2009;8(2): 175-178.
30. Smith CH, Jackson K, Bashir SJ, Perez A, Chew AL, Powell AM, et al. Infliximab for severe, treatment-resistant psoriasis: A prospective, open-label study. Br J Dermatol. 2006;155(1):160-169. (Pubitemid 43876410)
31. Torralba KD, Quismorio FP. Soft tissue infections. Rheum Dis Clin North Am. 2009;35(1):45-62.
32. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc. 2001;76:653-656. (Pubitemid 32525142)
33. Sangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-a agents. J Am Med Assoc. 2009;301(7):737-744.
34. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and United Kingdom. Arthritis Rheum. 2007;57(8):1431-1438. (Pubitemid 350308841)
35. Dixon WG, Watson K, Lunt M, Hyrich KL. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006; 54(8):2368-2376. (Pubitemid 44204996)
36. Esposito S. Immune system and surgical site infection. J Chemother. 2001;1(1):12-16. (Pubitemid 34183587)
37. Topstad DR, Panaccione R, Heine JA, Johnson DRE, MacLean AR, Buie WD. Combined seton placement, infliximab infusion and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease. Dis Colon Rectum. 2003;46:577-583. (Pubitemid 36576412)
38. Gaertner WB, Decanini A, Mellgren A, Lowry A, Goldberg SM, Madoff RD, et al. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum. 2007;50(11):1735-2012.
39. Kunitake H, Hodin R, Shellito PC, Sands BE, Korzenik J, Bordeianou L. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12:1730-1737.
40. Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: A controlled cohort study. Aliment Pharmacol Ther. 2004;19:749-754. (Pubitemid 38496640)
41. Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol. 2004;99:878-883. (Pubitemid 39090217)
42. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133.
43. Schluender S, Ippoliti A, Dubinsky M, Vasiliauskas EA, Papadakis KA, Mei L, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum. 2007;50: 1747-1753. (Pubitemid 350077092)
44. Selvasekar C, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg. 2007;204(5): 956-962. (Pubitemid 46661200)
45. Bongartz T. Elective orthopedic surgery and perioperative DMARD management: Many questions, fewer answers, and some opinions. J Rheumatol. 2007;34(4):653-655. (Pubitemid 46641364)
46. Talwalkar SC, Grennan DM, Gray J, Johnson P, Hayton MJ. Tumor necrosis factor antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005;64(4):650-651. (Pubitemid 40469105)
47. Wendling D, Balblanc J-C, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor a treatment in rheumatoid arthritis: An observational study on 50 surgical procedures. Ann Rheum Dis. 2005;64:1378-1379. (Pubitemid 41206266)
48. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-a inhibition therapy. Foot Ankle Int. 2004;25:331-335. (Pubitemid 39096154)
49. den Broeder AA. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study. J Rheumatol. 2007;34(4): 689-695. (Pubitemid 46641372)
50. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study. Arthritis Rheum. 2002;46(9):2287-2293.
51. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59(12):1713-1720.
52. Hamalainen M, Raunio P, Von Essen R. Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol. 1984;3:329-335. (Pubitemid 15072114)
53. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Ann Rheum Dis. 2001;60:214-217. (Pubitemid 32260601)
54. Hernandez C, Emer J, Robinson JK. Perioperative management of medications for psoriasis and psoriatic arthritis: A review for the dermasurgeon. Dermatol Surg. 2008;34: 446-459. (Pubitemid 351442691)
55. Saini R, Shupack JL. Psoriasis: To cut or not to cut, what say you? Dermatol Surg. 2003;29:735-740. (Pubitemid 36870145)
56. Lynfield YL, Ostroff G, Abraham J. Bacteria, skin sterilization, and wound healing in psoriasis. N Y State J Med. 1972;72:1247-1250.
57. Noble WC, Savin JA. Carriage of Staphylococcus aureus in psoriasis. Br Med J. 1968;(i):417-418.
58. Lambert JR, Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil. 1979;18:35-37. (Pubitemid 9120785)
59. Beyer CA, Hanssen AD, Lewallen DG, Pittelkow MR. Primary total knee arthroplasty in patients with psoriasis. J Bone Joint Surg. 1991;73:258-259.
60. Hicken GJ, Kitaoka HB, Valente RM. Foot and ankle surgery in patients with psoriasis. Clin Orthop. 1994;300:201-206. (Pubitemid 24085498)
61. Stern SH, Insall JN, Windsor RE, Inglus AE, Dines DM. Total knee arthroplasty in patients with psoriasis. Clin Orthop Relat Res. 1989;248:108-111. (Pubitemid 20204789)
62. Menon TJ, Wroblenski BM. Charnley low friction arthroplasty in patients with psoriasis. Clin Orthop Relat Res. 1983;176:127-128. (Pubitemid 13068415)
63. Cheleuitte E, Fleischli J, Tisa L, Zombolo R. Psoriasis and elective foot surgery. J Foot Ankle Surg. 1996;35: 297-302. (Pubitemid 26299124)
64. LimaXT,SeidlerEM,LimaHC,KimballAB.Long-termsafety of biologics in dermatology. Dermatol Ther. 2009;22:2-21.
65. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Roxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Med Assoc. 2006;296:1735-1741. (Pubitemid 44547793)
66. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A, et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control study. J Am Acad Dermatol. 2007;56(4):629-634. (Pubitemid 46400186)
67. Neimann AL, Shin DB, Wang X, Margolis DJ, Roxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5): 829-835. (Pubitemid 44556851)
68. Pieringer H, Stuby U, Biesenbach G. Patients with rheumatoid arthritis undergoing surgery: How should we deal with antirheumatic treatment? Semin Arthritis Rheum. 2007;36: 278-286. (Pubitemid 46517632)
69. Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia A, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56(4):598-603. (Pubitemid 46400183)
70. Rosandich PA, Kelley JT, Conn DL. Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol. 2004;16: 192-198. (Pubitemid 38530485)